News
The first results from a study into the impact of cannabinoids on respiratory diseases have been published
Scientists at King’s College London, working in collaboration with Sativa Wellness Group have published the first results from a study into the impact of cannabinoids on respiratory diseases.
It aimed to investigate the anti-inflammatory effects of the two non-psychotropic cannabinoids alone and in combination, in a model of pulmonary inflammation.
According to a statement released by the company, the results of the work suggest that the CBD and CBG in combination have ‘significant anti-inflammatory activity’ in the lungs.
This builds on previous research suggesting cannabinoids are promising potential treatments for inflammatory diseases.
The research also identified that the formulation for administering cannabinoids is critically important to obtain efficacy.
Concluding, the authors wrote: “This study has provided evidence that CBD and CBG formulated appropriately exhibit anti-inflammatory activity.
“Our observations suggest that these non-psychoactive cannabinoids may have beneficial effects in treating diseases characterised by airway inflammation.”
Sativa Investments PLC announced that it had entered into a research agreement with King’s College London to study the impact of cannabinoids on inflammation and respiratory diseases in 2019.
Geremy Thomas, executive chairman said: “We have actively supported research now for over two years to identify the therapeutic benefits cannabinoids can have on medical conditions. Research is something we as a company believe is essential to inform the public and we are delighted to have seen such positive results identified.”
A round-up of the latest science, regulation and developments across the UK and Europe — in your inbox every week.
A round-up of the latest science, regulation and developments across the UK and Europe — in your inbox every week.